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Monoclonal antibodiesSmad-interacting protein 1 (SIP1, also known as ZEB2) represses the transcription of E-cadherin and
mediates epithelial–mesenchymal transition in development and tumor metastasis. Due to the lack of
human SIP1-specific antibodies, its expression in human tumor tissues has not been studied in detail by
immunohistochemistry. Hence, we generated two anti-SIP1 monoclonal antibodies, clones 1C6 and 6E5, with
IgG1 and IgG2a isotypes, respectively. The specificity of these antibodies was shown by Western blotting
studies using siRNA mediated downregulation of SIP1 and ZEB1 in a human osteosarcoma cell line. In the
same context, we also compared them with 5 commercially available SIP1 antibodies. Antibody specificity
was further verified in an inducible cell line system by immunofluorescence. By using both antibodies, we
evaluated the tissue expression of SIP1 in paraffin-embedded tissue microarrays consisting of 22 normal and
101 tumoral tissues of kidney, colon, stomach, lung, esophagus, uterus, rectum, breast and liver.
Interestingly, SIP1 predominantly displayed a cytoplasmic expression, while the nuclear localization of
SIP1 was observed in only 6 cases. Strong expression of SIP1 was found in distal tubules of kidney, glandular
epithelial cells of stomach and hepatocytes, implicating a co-expression of SIP1 and E-cadherin. Squamous
epithelium of the esophagus and surface epithelium of colon and rectum were stained with moderate to
weak intensity. Normal uterus, breast and lung tissues remained completely negative. By comparison with
their normal tissues, we observed SIP1 overexpression in cancers of the kidney, breast, lung and uterus.
However, SIP1 expression was found to be downregulated in tumors from colon, rectum, esophagus, liver
and stomach tissues. Finally we did nuclear/cytoplasmic fractionation in 3 carcinoma cell lines and detected
SIP1 in both fractions, nucleus being the dominant one. To our best knowledge, this is the first
comprehensive immunohistochemical study of the expression of SIP1 in a series of human cancers. Our
finding that SIP1 is not exclusively localized to nucleus suggests that the subcellular localization of SIP1 is
regulated in normal and tumor tissues. These novel monoclonal antibodies may help elucidate the role of
SIP1 in tumor development.y of Science, Department of
A, Turkey.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Smad-interacting protein 1 (SIP1, also known as ZEB2) encoded by
ZFHX1B is a member of ZEB family of transcription factors. The protein
contains a central homeodomain, CtBP-binding and Smad-interacting
domains and two zinc finger clusters each at either end (Remacle et al.,
1999; Verschueren et al., 1999). SIP1 directly binds to bipartite E-boxes
on the promoters of different targets bymeans of its zincfinger domains
andmediates transcriptional repression (Verschueren et al., 1999). One
of these targets is CDH1, the gene encoding for the epithelial adherensjunction protein E-cadherin, whose transcriptional downregulation
induces epithelial-to-mesenchymal transition (EMT) in developmental
processes and during tumor cell invasion and metastasis (Comijn et al.,
2001). Transcriptional repression ismediated through the association of
SIP1 with the corepressor CtBP, however this interaction is dispensable
at least for the attenuation of CDH1 transcription (Postigo et al., 2003;
van Grunsven et al., 2003). Overexpression of SIP1 in epithelial cells has
also been shown to downregulate constituents of cell–cell junctions
other than E-cadherin (Vandewalle et al., 2005). Although binding of
SIP1 to p300 or pCAF was proposed as a mechanism for transactivation
and other transcriptional activators associated to SIP1 are yet to be
determined, SIP1-mediated upregulation of EMT and invasion related
genes, such as vimentin and matrix metalloproteases, have been
reported (Bindels et al., 2006; Miyoshi et al., 2004; Postigo et al., 2003).
183E. Oztas et al. / Experimental and Molecular Pathology 89 (2010) 182–189Despite the overwhelming evidence that SIP1 induces EMT
phenotype, its role in tumorigenesis was ill-defined. In fact, SIP1 was
originally identified as a binding partner of R-Smads, and shown to be
part of the TGF-β pathway, which is frequently involved in carcinogen-
esis (Verschueren et al., 1999). hTERT repression in breast cancer cells
was partly mediated by SIP1 in a TGF-β dependent manner (Lin and
Elledge, 2003). Also, analysis of senescence arrest of clonal hepatocel-
lular carcinoma cells revealed SIP1 as a mediator of hTERT repression
(Ozturk et al., 2006). Impaired G1/S progression was observed upon
repression of cyclin D1 by SIP1 (Mejlvang et al., 2007). SIP1 was also
shown to contribute to tumorigenesis in a transgenic mouse model of
lymphoma by retroviral tagging (Mikkers et al., 2002). The differential
expression of SIP1 has been described, mostly by RT-PCR, in several
human tumors due to the lack of human SIP1-specific antibodies. E-
cadherin downregulationwas associated to increased SIP1 expression in
intestinal type gastric carcinoma but not in diffuse type gastric
carcinoma (Rosivatz et al., 2002). Elevated SIP1 expression correlated
inversely with E-cadherin in advanced stages of pancreatic tumors
(Imamichi et al., 2007). Surprisingly, SIP1 and E-cadherin expression
were positively correlated in malignant mesothelioma (Sivertsen et al.,
2006). In the esophagus, differential expression of SIP1 was observed
duringkeratinocyte differentiation.Only stemcell containingbasal cells,
but not parabasal cells and keratinocytes expressed SIP1. Consistent
with this, SIP1 transcripts were present in all studied esophagealFig. 1. Endogenous and induced expression of SIP1 is detected by monoclonal antibodies 1C6
(ZEB1-si) siRNAs. Proteins were extracted 48 h after transfection and western blot was perfo
antibodies. Both SIP1 antibodies did not recognize ZEB1 and can detect endogenous SIP1 ef
compare the new SIP1 MAbs with 5 different commercial antibodies. The results from polycl
are presented in left and right panels, respectively. With the exception of 474, all other comm
in 2 μg doxycycline for 24 h and stained with 6E5 MAb displayed nuclear SIP1 expression (fi
(second row).carcinoma cases (Isohata et al., 2009). High SIP1/E-cadherin ratio
correlated with metastatic disease and poor patient survival in breast
and ovarian carcinomas (Elloul et al., 2005). Elevated SIP1 transcripts
were observed in von Hippel–Lindau-null renal cell carcinomas in a
hypoxia-inducible factor 1 alpha (HIF1α)-dependent manner (Krish-
namachary et al., 2006). Immunohistochemical analysis of ovarian
tumors revealed a stepwise increase of SIP1 frombenign to borderline to
malignant tumors (Yoshida et al., 2009). In oral squamous cell
carcinoma, SIP1 was immunohistochemically detected in a relatively
low proportion of tumors and its expression correlated with poor
prognosis (Maeda et al., 2005). In a previous study, we have found that
SIP1was overexpressed in a series of bladder cancers. Its expressionwas
found to be an independent prognostic factor in bladder cancers and
positively stained cases correlated with poor therapeutical outcome
(Sayan et al., 2009).With the exception of a few and as described above,
most of the expression studies of SIP1 were done using RT-PCR
technique, but SIP1protein levels have been shown to be tightly
regulated by post-transcriptional mechanisms. For instance, Pc2-
mediated sumoylation of SIP1 affects the transcriptional regulation of
E-cadherin (Long et al., 2005). SIP1 has been identified as a direct target
of miR-200 family andmiR-205 (Gregory et al., 2008; Park et al., 2008).
In this study, we generated 2 new monoclonal antibodies (MAb)
against the N-terminus of SIP1 protein and validated their specificity
by specifically downregulating SIP1 protein, and the other ZFHX1and 6E5. (A) HOS2 cells were transfected with control (Neg-si), SIP1 (SIP1-si) and ZEB1
rmed with the indicated antibodies. SIP1 specific band was detected with 1C6 and CUK
ficiently. (B) Control siRNA and SIP1 siRNA transfected HOS2 cell lysates were used to
onal antibodies (goat or rabbit anti-SIP1) and monoclonal antibodies (mouse anti-SIP1)
ercial antibodies were either weak or non-specific. (C) A431/WTSIP1 cells maintained
rst row), whereas no staining was observed in uninduced cells with the same antibody
Table 1
Immunohistochemistry results of SIP1 expression in human tissues.
Tissue (n=123) SIP1 expression
Cytoplasm Nucleus SIP1-positive structure
Kidney
Tumor (n=18) +++ (17) − Tumoral cells
Normal (n=4) ++ (4) − Proximal–distal tubules
Lung
Tumor (n=14) + (10) − Tumoral cells
Normal (n=3) − (0) − Surfactant ++(3)
Breast
Tumor (n=9) + (5) − Tumoral cells
Normal (n=2) − (0) − −
Uterus
Tumor (n=12) + (5) − Tumoral cells
Normal (n=3) − (0) − −
Liver
Tumor (n=9) ++ (9) − Tumoral cells
Normal (n=2) +++ (2) − Hepatocytes
Stomach
Tumor (n=9) + (4) − Tumoral cells
Normal (n=1) +++ (1) − Glandular cells
Colon
Tumor (n=12) + (4) − Tumoral cells
Normal (n=4) ++ (4) + (4) Surface epithelium
Rectum
Tumor (n=9) + (7) ++ (1) Tumoral cells
Normal (n=1) ++ (1) ++ (1) Surface epithelium
Esophagus
Tumor (n=9) + (5) − Tumoral cells
Normal (n=2) ++ (2) − Squamous epithelium
Mean staining intensities expressed as (−): negative, +: weak, ++: moderate, +++:
strong. Numbers in parentheses represent positively stained cases.
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using these antibodies we explored the expression pattern of SIP1 in
human tumor cell lines and in a variety of tissues. We detected
predominantly cytoplasmic but also nuclear SIP1 staining. Finally,
subcellular fractionation of cell lines showed that SIP1 protein can be
present in the cytoplasm and nucleus of multiple carcinoma cell lines.
To our knowledge, this study is the first description of SIP1 protein
expression in a multiple tumor tissue arrays.
Materials and methods
Cell lines, tissues and siRNA transfections
Wild-type mouse SIP1 expressing squamous epidermoid carcino-
ma cell line A431/WTSIP1 with Tet-on doxycycline-inducible SIP1
expression was previously described (Mejlvang et al., 2007).
Osteosarcoma cell line HOS2, hepatocellular carcinoma cell line SK-
HEP-1 and colorectal carcinoma cell lines SW480 and SW620 were
maintained in DMEM supplemented with 10% fetal bovine serum,
100 IU penicillin, 100 μg streptomycin and nonessential amino acids.
Multiple Tumor Tissue arrays were purchased from BioChain Institute,
Inc. (Hayward, CA). siRNAs targeting ZEB1 (Sayan et al., 2009) and
SIP1 (S102364277, Qiagen, Hilden, Germany) were transfected using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Cells were
collected 48 h after transfection and processed for Western blotting.
Recombinant SIP1 production
The first 360 amino acid part coding region of SIP1 (ZEB2) cDNA was
cloned into pET101/D (Invitrogen, Carlsbad, CA) vector with an N-
terminal 6-histidine tag. Recombinant protein was expressed in
Escherichia coli (BL21) and purified under denaturing conditions using
Ni–NTA resin (Qiagen, Hilden, Germany). Purified protein then was
refolded and buffer exchanged to phosphate buffered saline (PBS) using
NAP buffer exchange columns (Amersham, Piscataway, NJ). Finally, pure
and folded recombinant protein was concentrated (0.5–1 mg/ml) using
Centripreps (Millipore, Billerica, MA).
Production of monoclonal antibodies
Recombinant SIP1 protein was injected into the peritoneal cavity of
8- to 10-week-old BALB/c mice at 3 week intervals. During the
immunization period, antibody titer of mice sera was evaluated by
indirect ELISA. Briefly, ELISA plates were coated by 100 ng of
recombinant SIP1 protein in carbonate buffer (pH: 9.6). Serially diluted
mice sera were assessed for their immunoreactivity with SIP1 protein.
Alkaline phosphatase conjugated goat anti-mouse IgG (Sigma-Aldrich,
St. Louis, MO) was used as secondary antibody. Colorimetric reaction
generated upon addition of the substrate para-nitrophenyl-phosphate
(Sigma-Aldrich, St. Louis, MO) was measured at A405 in an automated
plate reader (Biotek Instruments, Winooski, UT). Three days after the
final boost, fusion of mouse splenocytes and SP2/0 myeloma cells was
performed as previously described (Celikkaya et al., 2007). Hybridoma
supernatants were screened by aforementioned indirect ELISA, and
hybridomas secreting anti-SIP1 antibodies were subjected to single cell
subcloning. Antibody isotype was determined by ImmunoPure Mono-
clonal Antibody Isotyping Kit (Pierce, Rockford, IL) according to
manufacturer's instructions.
Western blotting
Total cell lysates from HOS2, SK-HEP-1, SW480 and SW620 cell
lines were prepared in NP-40 lysis buffer [50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% Non-idet P40 (v/v) and a cocktail of EDTA-free
protease inhibitors (Roche Diagnostics, Mannheim, Germany)] or by
direct lysis in 2X Laemmli buffer. Nuclear and cytosolic proteinfractions were prepared by NE-PER® Nuclear and Cytoplasmic
Extraction Reagents (Pierce, Rockford, IL) according to manufacturer's
instructions. Protein content was measured by Bradford or BCA assay.
Equalized lysates were run on 8% SDS-PAGE and then transferred onto
polyvinylidene fluoride (PVDF) membranes by using semi-dry
transfer apparatus (Bio-Rad, Hercules, CA). 1C6 and 6E5 hybridoma
supernatants were used as primary antibody. Other antibodies used in
this study are from Bethyl Labs [473 (A302-473A) and 474 (A302-
474A), 1:500; Montgomery, TX], Santa Cruz [SC1 (sc-48789) and SC2
(sc-18392), 1:500; Santa Cruz, CA] and Sigma (WH0009839M1,
1:500; Sigma-Aldrich, St. Louis, MO) for SIP1 immunodetection and
Santa Cruz (sc-25388,) for ZEB1 immunodetection. Rabbit polyclonal
SIP1 antibody (CUK2) was previously described (Sayan et al., 2009).
Horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit
IgG or anti-goat (Sigma-Aldrich, St. Louis, MO) were used as
secondary antibodies at 1:5000 dilution. Protein bands were visual-
ized using Super Signal West Dura or Femto chemiluminescent
substrate (Pierce, Rockford, IL).
Quantitative real-time PCR
SIP1 mRNA expression in colon cancer cell lines SW620, SW480
and hepatocellular carcinoma cell line SK-HEP-1 was determined by
quantitative real-time PCR as described previously (Avci et al.,
2008). The expression of SIP1 in cell lines was measured using
ΔΔCt method and normalized to GAPDH gene. The threshold cycle
of SIP1 cDNA in SW480 cell line, which showed the lowest
expression was set to 1 and relative expression values were plotted
as fold changes.
Immunofluorescence
A431/WTSIP1 cells were grown on cover slips in 6 well plates and
inducedwith doxycycline (2 μg/ml) for 24 h. PBSwas used in allwashing
185E. Oztas et al. / Experimental and Molecular Pathology 89 (2010) 182–189steps. Cells were fixed in 2% paraformaldehyde in PBS and permeabilized
in PBS containing 0.3% triton X-100. After blockingwith 2% Bovine Serum
Albumin (BSA) in PBS, cells were incubated for 2 h at room temperature
with hybridoma supernatants. Alexa fluor 488-conjugated anti-mouse
IgG (Invitrogen, Carlsbad, CA) was used as secondary antibody at 1:200
dilution. Nuclei counterstaining was performed with 4′,6-diamidino-2-
phenylindole (DAPI); cover slips were mounted on glass slides and
examined under fluorescent microscope (Zeiss GmbH, Germany).
Merged images were produced by using AxioVision image processing
software (Zeiss GmbH, Germany).Fig. 2. Increased expression of SIP1 in kidney, lung, breast and uterus tumors. Representa
tissues as detected by immunohistochemistry performed by both antibodies. (A) Distal
(D) adenocarcinoma of the uterus, (E) normal lungwith non specific surfactant staining, (F
(−): negative, +: weak, ++: moderate, +++: strong staining intensity (scale bars: 50 µImmunohistochemistry
A total of 123 tissues spotted on three tissue arrayswere stained twice
by both 1C6 and 6E5 MAbs. Tissue arrays included sections from kidney
(22: tumor18,normal4), lung (17: tumor14,normal3), colon (16: tumor
12, normal 4), uterus (15: tumor 12, normal 3), esophagus (11: tumor 9,
normal 2), liver (11: tumor 9, normal 2), breast (11: tumor 9, normal 2),
rectum (10: tumor 9, normal 1) and stomach (10: tumor 9, normal 1)
tissues. Tissue array slides were deparaffinized first at 70 °C and then in
xylene. After rehydration in graded alcohol series, glass slides weretive photographs show increased SIP1 expression in tumors relative to their normal
tubule staining in normal kidney, (B) clear cell renal carcinoma, (C) normal uterus,
) squamous cell carcinoma of the lung, (G) normal breast, (H) breast ductal carcinoma.
m).
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oven for 20 min for antigen retrieval. Endogenous peroxidase was
blocked by incubation of slides in 3% H2O2 for 30 min. PBS was used in
all washing steps. Tissue sections were incubated with hybridoma
supernatants for 2 h, and after washing, universal staining kit (LabVision,
Fremont, CA) was used according to manufacturer's recommendations.
3,3′-diaminobenzidine (DAB)wasusedas chromogenand the slideswere
counterstained using Mayer's hematoxylin. Stainings were performed in
triplicate for both antibodies. The sections were evaluated by light
microscopic examination and the intensity of immunostaining in each
section was assessed independently by two observers (E.O and A.O). The
intensity of total SIP1 staining on each sample was scored as previously
described with a slight modification (Chen et al., 2006). Briefly the
staining intensitywasgraded relativelybasedon the following scales: 0, 1,
2, and3 fornegative,weak,moderate and strong staining, respectively. An
averaged scorewas reachedas thefinal score for each tissuewithmultiple
samples. According to the final immunostaining scores, the tissues were
classified into four groups: negative group (score 0–0.40), weak staining
group (score 0.5–1.4), moderate staining, group (scores 1.5–2.4), and
strong staining group (scores 2.5–3). (−), (+), (++) and (+++)
designationswere used for these four groups, respectively. The staining in
nuclei and cytoplasm was determined separately on each specimen.Results
Monoclonal antibodies 1C6 and 6E5 detect both endogenous and
overexpressed SIP1
Two MAbs, clones 1C6 and 6E5 were obtained by immunizing
BALB/c mice with a partial human SIP1 recombinant protein (aa 1-
360). The isotypes of antibodies were IgG2a and IgG1, respectively
(data not shown). ZEB1 and SIP1 (ZEB2) are members of the zinc
finger Homeobox 1 gene family. Among these 2 proteins, there is
more than 45% overall protein homology which is much higher (up to
93% identity at C-terminal zinc finger cluster) in the functional
domains (Vandewalle et al., 2009). Thus, as a first step, we wanted to
assess the specificity of the new antibodies by specifically knocking
down ZEB1 and SIP1 proteins in HOS2 osteosarcoma cells. As shown in
Fig. 1A, endogenous SIP1 was specifically downregulated by SIP1
siRNA but not by ZEB1 siRNA and detected by 1C6 MAb. The
authenticity of 1C6 immunoreactive band (190 kDa) is also confirmed
by another SIP1 antibody (CUK2). None of the SIP1 antibodies
detected ZEB1 and ZEB1 antibody did not detect SIP1 (Fig. 1A). As a
second step, we wanted to test the specificity and strength of several
other commercial SIP1 antibodies. We used control siRNA and SIP1
siRNA transfected HOS2 cell lysates to detect endogenous SIP1. With
the exception of 474, which recognized endogenous SIP1 weakly,
commercial polyclonal SIP antibodies were either very weak (SC1,
SC2) or non-specific (473) (Fig. 1B, left panel). Also, when compared
with another MAb (Sigma), only 1C6 and 6E5, but not the com-
mercial one recognized SIP1 specifically (Fig. 1B, right panel). The
specificity of these new SIP1 MAbs were also validated in the
inducible cell line system A431 containing mouse WTSIP1. By using
both antibodies in immunofluorescence assay, we detected nuclear
expression of SIP1 in these cells maintained in the presence of
doxycycline for 24 h (Fig. 1C). These results showed that the new SIP1
MAbs are specific and able to detect SIP1 in endogenous levels and
when overexpressed.Fig. 3. Reduced expression of SIP1 in liver, stomach, colon, rectum and esophagus tumo
antibodies and show decreased SIP1 expression in tumors with respect to their normal tissue
the adjacent cirrhotic tissue, (C) normal stomach gland cells, (D) adenocarcinoma of the stom
rectum surface epithelium, (H) adenocarcinoma of the rectum, (I) normal esophagus squamo
+++: strong staining intensity (scale bars: 50 µm).Tissue expression of SIP1 is predominantly cytoplasmic
Next, the tissue expression pattern of SIP1 proteinwas analyzed by
staining formalin-fixed and paraffin-embedded tissue arrays with
MAbs 1C6 and 6E5. 22 normal and 101 tumor tissues were examined
by immunohistochemistry and all samples displayed similar reactivity
upon staining by both clones. The SIP1 immunostaining pattern of
tissues was summarized in Table 1. No immunoreactivity was
observed in tissue arrays stained with mouse IgG1 and IgG2a isotype
control antibodies (data not shown).
The majority of tissues displayed cytoplasmic staining of SIP1 and
nuclear expression of SIP1 was observed only in 6 cases consisting of
one normal and one tumor tissues of rectum and four normal colon
samples (Table 1).
Differential expression of SIP1 in human tumors
SIP1 is overexpressed in tumors of the kidney, lung, breast and uterus
1C6 and 6E5 antibodies stained both proximal and distal tubules of
kidney, yet the reactivity of the latter was more intense. Compared to
the tubular epithelium-restricted expression of SIP1 in normal kidney,
SIP1 was extensively expressed in kidney tumors. Out of 18 tumors,
17 clear cell carcinomas displayed strong cytoplasmic staining with
both antibodies (Fig. 2A–B), and one transitional cell carcinoma case
remained negative. Relative to their normal tissues, which failed to
display SIP1 expression, 71% of lung, 56% of breast and 42% of uterus
tumors showed cytoplasmic SIP1 positivity, yet with a weak intensity
(Fig. 2C–H).
Cytoplasmic SIP1 is downregulated in most of the human tumors
The cytoplasm of all 9 hepatocellular carcinoma cases displayed a
moderate intensity of SIP1 expression, which could not reach
however the strong staining pattern of SIP1 in normal hepatocytes
and tumor-adjacent cirrhotic tissues (Fig. 3A, B). Eight of nine
stomach adenocarcinomas were weakly positive for SIP1 expression,
a pattern far beyond the intense SIP1 staining of glandular cells of
normal stomach (Fig. 3C, D). Apical crypt epithelia of 4 normal colon
samples displayed cytoplasmic staining with both antibodies with
moderate intensity, and a faint nuclear SIP1 expression was also
observed in these cells. However, only 4 of 12 colon tumors were
weakly positive for cytoplasmic SIP1 (Fig. 3E, F). In tissue arrays, only
one normal rectum sample was available, and lumen-facing epithelial
cells of this tissue were found to express SIP1 mainly in their nuclei
and to a lesser extent in their cytoplasm. Irrespective of its cellular
localization, SIP1 expression was of moderate to strong intensity in
normal rectum. On the contrary, 78% of rectum tumors were stained,
but with weak immunoreactivity (Fig. 3G, H). The dominant
cytoplasmic staining pattern of these cancer tissues was accompanied
by moderate nuclear staining in only one case, which was the tumor
with most advanced stage among others (data not shown). Tumor
cells of 5 squamous cell carcinoma of the esophagus expressed SIP1,
yet with a weaker intensity than squamous epithelium of normal
esophagus, which was stained with moderate intensity by both
antibodies (Fig. 3I, J).
Cytoplasmic SIP1 is present in tumor cell lines
Cytoplasmic SIP1 expression in the majority of human carcinomas
prompted us to validate this observation in two colon cancer cell lines
(SW620 and SW480) and one hepatocellular carcinoma cell line (SK-rs. Photographs are representative from immunohistochemistry performed by both
s. (A) Normal liver, (B—right) hepatocellular carcinoma (HCC) of the liver and (B—left)
ach, (E) normal colon surface epithelium, (F) adenocarcinoma of the colon, (G) normal
us epithelium, (J) squamous cell carcinoma of the esophagus. +: weak, ++:moderate,
Fig. 4. SIP1 protein is present in nucleus and cytoplasm of carcinoma cell lines.
(A) Western blotting performedwith clone 1C6 shows strong SIP1 expression at 190 kDa in
the nuclear fraction of SK-HEP-1 cells, yet the antibody also detects bands with lower
molecular weight proteins in nuclear (N) and total cell lysates (T) of all 3 cell lines. SIP1
expression is more apparent in the cytoplasmic (C) but not nuclear extracts of SW480 and
SW620cells. SK-HEP-1cells also contain similar levels of cytoplasmic SIP1. (B)Quantification
of SIP1 transcripts indicates the highest SIP1 expression in SK-HEP-1 cell line. SIP1 transcript
levels in SK-HEP-1 and SW620 cells are represented as fold changes with respect to SW480
reference cell line.
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SIP1 protein byWestern blotting. A protein band with strong intensity at
the expected size (190 kDa) of SIP1 was observed in the nuclear fraction
of the invasive hepatocellular carcinoma cell line SK-HEP-1 (Fig. 4A).
Weaker protein bands of the same size also appeared in the cytosolic
fractionof SK-HEP-1, and inboth cytosolic andnuclear fractions of SW620
and SW480 cells. However, SIP1 expressionwas barely detectable in total
cell lysates. Besides, SIP1 antibody immunoreactive bands at about
120 kDa and lower molecular weights were also observed in the nuclear
extracts and total cell lysates of all 3 cell lines (Fig. 4A). These resultswere
in accordance with real-time quantitative PCR data in which SK-HEP-1
was the cell line with most abundant SIP1 transcript (Fig. 4B).
Overall, our results indicated that SIP1 was widely expressed in
most normal human tissues that we examined, with moderate to
strong intensities, and the overexpression of SIP1was confined only to
a restricted group of human tumors.
Discussion
SIP1 has been reportedly shown to mediate EMT and disease
aggressiveness in human tumors (Comijn et al., 2001; Elloul et al.,
2005). Several studies indicated increased levels of SIP1 transcripts in
association with invasion and metastasis in cancers with advanced
stages (Imamichi et al., 2007; Miyoshi et al., 2004). However, a
comprehensive study on SIP1 protein expression in human normal
and tumors tissues has not been performed. We produced two MAbs
using the N-terminal 360 amino acids of human SIP1 protein as an
antigen and assessed their immunoreactivity in cell lines and tissue
arrays. As an initial study we downregulated SIP1 and the other
ZFHX1 family member protein, ZEB1, by siRNA in an osteosarcoma
derived cell line and compared the strength and specificity of the
novel SIP1 antibodies along with 5 different commercial SIP1
antibodies. We found that 1C6 and 6E5 can detect endogenous SIP1,but not ZEB1, in this system strongly and specifically. We also
observed that, with the exception of Bethyl Labs 474 antibody, all
other commercial SIP1 antibodies are weak or non-specific. Close
homology between human and mouse SIP1 proteins allowed us to
evaluate the specificity of novel SIP1 antibodies in overexpression
studies. Immunofluorescence analysis of A431/WTSIP1 cells with Tet-
on doxycycline-inducible wild-type mouse SIP1 expression revealed
nuclear localization of SIP1 in only doxycycline-induced cells. This
result also suggests that 1C6 and 6E5 recognize epitopes shared in
both human and mouse proteins.
Endogenous SIP1 expression was analyzed in HCC cell line SK-
HEP-1 and colorectal cancer cell lines SW480 and SW620. SK-HEP-1 is
a well-known invasive hepatocellular carcinoma cell line (Lin et al.,
1998); SW480 and SW620 cell lines were established from the
primary and metastatic tumors of the same patient, respectively
(Leibovitz et al., 1976). Consistent with the role of SIP1 in inducing
EMT phenotype, we found higher SIP1 transcript levels in SW620 and
SK-HEP-1 cells compared to SW480 cell line. SIP1 expression analysis
in western blot and qRT-PCR was almost consistent with a basal
expression in SW620 and SW480, and an apparent upregulation in
SK-HEP-1. Although there was a ∼15 fold SIP1 overexpression in
metastatic SW620 cells when compared to SW480, the significance of
this difference is questionable given the SIP1expression in SK-HEP-1
in thousands scale. Moreover, Western blotting revealed protein
bands other than the expected 190 kDa size of SIP1 protein. In fact, a
comprehensive analysis through human and mouse tissues revealed
multiple transcripts of SIP1 in both species (Bassez et al., 2004). Taken
together with the immunofluorescence data, these results suggest
that SIP1 protein expression is tightly regulated, andmay also indicate
the existence of alternative SIP1 transcripts. However, at this point,
we cannot exclude the possibility of non-specific signal or protein
degradation for the aforementioned protein bands with lower
molecular weights.
In contrast to nucleus-restricted expression of SIP1 in A431 Sip1
inducible system, most of the analyzed tissues displayed cytoplasmic
protein expression. One explanation might be that while cell lines are
grown in isolation in culture, tissues are subject to signals from their
neighboring cells that may regulate intracellular SIP1 localization.
Additionally, cellular stress induced by continuous culture of cell lines
may affect the intracellular SIP1 destination. Consistent with our
immunohistochemistry findings, a recent report also indicated
cytoplasmic expression of SIP1 in ovarian tumors (Yoshida et al.,
2009). Strong SIP1 expression in normal epithelial cells including
hepatocytes, kidney tubules, stomach glandular epithelium and colon
surface epithelium suggests the co-existence of E-cadherin and SIP1.
Moreover, SIP1 appears to be prevented from translocating into
nucleus in these tissues. It is therefore plausible to state that, unlike
ZEB1, SIP1 and E-cadherin expression is not necessarily mutually
exclusive. Among the analyzed tissues, most of the normal tissues
expressed SIP1 from moderate to strong intensity, and we found SIP1
overexpression only in kidney, breast, lung and uterus tumors. On one
hand, this differential expression may suggest a protective role for
SIP1 against tumorigenesis. In fact, SIP1 was shown to directly repress
cyclin D1 (Mejlvang et al., 2007). Also, induced expression of SIP1 was
reported to be partly responsible for hTERT repression in hepatocel-
lular carcinoma cells (Ozturk et al., 2006). On the other hand, SIP1
may be implicated in tumor development irrespective of its role in
inducing EMT. In accordance with our results that SIP1 was
upregulated in some tumors, we recently showed that SIP1 protects
cancer cells from DNA damage-induced apoptosis (Sayan et al., 2009).
Also, SIP1 takes part in the TGF-β pathway and the effects of TGF-β on
cells are variable and depend on many factors including cell type and
physiological state of tissues (Massague, 2008; Postigo, 2003).
Given the functional role of SIP1 as a transcriptional repressor, this
and aforementioned studies suggest additional levels of regulation on
SIP1 activity in tumors in a tissue and/or context-dependent manner.
189E. Oztas et al. / Experimental and Molecular Pathology 89 (2010) 182–189Downstream to TGF-β signaling, ZEB1 and SIP1 regulate transcription of
target genes in conjunction with SMADs and CtBPs. ZEB1 and SIP1 were
shown to have opposing effects on transcriptional regulation (Postigo,
2003). A feedback mechanism was described in which ZEB1 and SIP1
show antagonism by differential recruitment of coactivators and
corepressors to SMAD complexes, respectively (Postigo et al., 2003). In
addition, the expression of ZEB1 and SIP1 was shown to be down-
regulated bymicro RNAs (Gregory et al., 2008). The effects of these post-
transcriptional regulation mechanisms on SIP1 protein might be
explored by using these novel MAbs in further functional studies.
Herein, we performed a pilot study for the understanding of tissue/
tumor specific SIP1 protein expression with the newly developed SIP1
specific antibodies using multi-tissue arrays. We showed that SIP1
protein levels increased only in a restricted group of tumors and most
normal tissues displayed SIP1 expression at some extent. We feel to
stress a drawback of staining multi-tumor arrays as the DAB color
reaction has to be stoppedwhen a detectable signal frommajority of the
samples is observed. Thus, our staining is optimal for high/mediumSIP1
expressing tissues andmaybe sub-optimal for lowSIP1 expressingones.
Lower SIP1 expressing tissues may have to be re-tested at their optimal
conditions for the better understanding of SIP1 function in tumor
development. Our recent paper that we analyzed SIP1 expression by
immunohistochemistry and described SIP1 protein overexpression as a
marker of poor prognosis in bladder cancers is a good example that SIP1
can be identified as a pro-metastatic protein (Sayan et al., 2009).
In conclusion our observation that SIP1 localized predominantly to
the cytoplasm in both tumor and normal tissues suggests the
implication of unidentified regulatory mechanisms that prevent
translocation of SIP1 into the nucleus. This, in turn, adds another level
of complexity to the control of EMT program in tumors progressing
towards metastatic state. Therefore, our findings bring novel opportu-
nities to further elaborate the role of SIP1 in tumor development.
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